Business Wire

HCHF

13.5.2020 23:03:10 CEST | Business Wire | Press release

Share
Worldwide Prayers for an End to Coronavirus Pandemic

In response to the Higher Committee of Human Fraternity (HCHF) calls to pray for humanity today, 14th May, people of all races, colours, ethnicities, and nationalities stood together in an unprecedented event to pray and supplicate to God for an end to the COVID-19 pandemic, and to guide and inspire scientists find a vaccine.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200513005852/en/

From the very first moment the HCHF announced its great initiative, the call gained the blessing and support of the two most prominent religious leaders in the world; His Eminence Dr. Ahmed El-Tayeb, Grand Imam of Al Azhar, and His Holiness Pope Francis, Pope of the Catholic Church, and received the support of a number of kings, presidents, leaders, and leading political, religious, and media figures from all the world.

Judge AbdelSalam, Secretary-General of the HCHF, held an online press conference on Monday, attended by Monsignor Yoannis Lahzi Gaid, Personal Secretary of His Holiness Pope Francis, and Irina Bokova, Former Director General of UNESCO during which he announced the details of the initiative in the presence of local and international media outlets.

Judge Mohamed AbdelSalam stated: “This support for the initiative is clear evidence that we can, especially when addressing common challenges, put aside our disagreements under the banner of our human fraternity. Believing that our common human values is the driving force for the HCHF’s members to announce the call to pray, fast and perform charitable work to rid mankind of this pandemic and its consequences.”

Judge AbdelSalam also announced the launch of the official website of the ‘Pray for Humanity’ initiative (pray.forhumanfraternity.org), which will provide live coverage of the day and will serve as a digital archive for this historic day and future events of the HCHF.

The HCHF was established to implement the humanitarian principles advocated by the Document on Human Fraternity and engage all religious and international organisations in this process to achieve peace, coexistence, global citizenship and human fraternity.

The HCHF consists of a group of influential figures of diverse religious and cultural backgrounds and experts in the fields of Inter-culture communication, interfaith dialogue and social coexistence:

  • Cardinal Miguel Ángel Ayuso Guixot, President of the Pontifical Council for Interreligious Dialogue of the Holy See,
  • Professor Mohamed Hussein Mahrasawi, President of Al-Azhar University,
  • Judge Mohamed Mahmoud AbdelSalam, Former Advisor to the Grand Imam of Al-Azhar and the Secretary-General of the Committee,
  • Rabbi M. Bruce Lustig, Senior Rabbi at Washington Hebrew Congregation,
  • Irina Bokova, Former Director General of UNESCO,
  • H.E. Mohamed Khalifa Al Mubarak, Chairman of the Department of Culture in Abu Dhabi,
  • Monsignor Yoannis Lahzi Gaid, Personal Secretary of His Holiness Pope Francis,
  • Dr. Sultan Al Remeithi, Secretary-General of the Muslim Council of Elders,
  • Leymah Gbowee, a Liberian peace activist and Nobel Peace Laureate,
  • Yasser Hareb, Emirati Writer and TV Presenter
  • Father Professor Dr. Ioan Sauca, the Secretary-General of the World Council of Churches.

*Source: AETOSWire

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye